PTC Therapeutics, Inc. (PTCT) Stock
Fundamentals
Recent news

PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
PTCT

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PTCT

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
PTCT

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates
PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates
PTCT
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.43 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
PTCT

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PTCT

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
PTCT

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates
PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates
PTCT

Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
PTCT

What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
PTCT

Reasons Why Investors Should Consider Betting on PTC Stock Now
Reasons Why Investors Should Consider Betting on PTC Stock Now
PTCT

Stocks Look Shaky, But This Sector is Booming (Biotech)
Stocks Look Shaky, But This Sector is Booming (Biotech)
PTCT

PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know
PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know
PTCT

CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
PTCT
About PTC Therapeutics, Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | CEO & Director | 1972 |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder & Independent Director | 1946 |
| Mr. Pierre Gravier M.S. | Chief Financial Officer | 1985 |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 1967 |
| Mr. Eric Pauwels | Chief Business Officer | 1962 |
| Dr. Lee Scott Golden M.D., Ph.D. | Executive VP & Chief Medical Officer | 1968 |
| Ms. Christine Utter CPA | Senior VP, Chief Accounting Officer & Head of People Services | 1979 |
| Ms. Linda Montella Carter | Senior VP & Chief Information Officer | — |
| Ms. Ellen Cavaleri | Head of Investor Relations | — |
| Mr. Mark Elliott Boulding J.D. | Executive VP & Chief Legal Officer | 1961 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
5 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.4 | +0.5 | -5.5 | +10.9 | ||||||||
| 2022 | -5.5 | -13.3 | +8.7 | -14.8 | -18.8 | +37.8 | +4.1 | +11.3 | -3.0 | -25.4 | +10.0 | -8.1 |
| 2023 | +20.3 | -7.8 | +7.1 | +16.3 | -23.9 | -6.5 | -2.6 | -2.9 | -44.1 | -11.7 | +24.8 | +14.9 |
| 2024 | -7.0 | +8.3 | -9.0 | +12.5 | +6.4 | -18.3 | +8.6 | +8.0 | +11.0 | +10.7 | +8.4 | -13.3 |
| 2025 | +0.0 | +10.5 | -3.6 | +7.0 | -2.0 | +0.0 | +7.2 | -5.4 | +17.1 | +10.2 | +26.6 | -4.1 |
| 2026 | -1.6 | -8.9 | +2.7 | -5.4 | +13.4 | +10.5 | -16.4 | +2.1 | -11.2 |



